May & Baker Nigeria Plc (MAYBAK.ng) 2021 Annual Report
May & Baker Nigeria Plc (MAYBAK.ng) listed on the Nigerian Stock Exchange under the Pharmaceuticals sector has released it’s 2021 annual report.
For more information about May & Baker Nigeria Plc reports, abridged reports, interim earnings results and earnings presentations visit the May & Baker Nigeria Plc company page on AfricanFinancials.
Indicative Share Trading Liquidity
The total indicative share trading liquidity for May & Baker Nigeria Plc (MAYBAK.ng) in the past 12 months, as of 2nd March 2022, is US$458.89K (NGN412.25M). An average of US$38.24K (NGN34.35M) per month.
May & Baker Nigeria Plc Annual Report Document
Company Profile
May & Baker Nigeria Plc manufactures and markets a range of pharmaceuticals, vaccines, medical diagnostics, foods and consumer healthcare products in Nigeria. Pharmaceutical products include anti-diabetics, anti-infectives, anti-malaria, analgesics, cough & cold treatments, multivitamins and anxiolytics. May & Bake Nigeria Plc produce a range of Mimee noodles and Lily still water. The company’s head office is in Lagos, Nigeria. May & Baker Nigeria Plc is listed on the Nigerian Stock Exchange
Recent Documents & News
-
Interim Reports
May & Baker Nigeria Plc (MAYBAK.ng) Q12023 Interim Report – April 28, 2023 -
Annual Reports
May & Baker Nigeria Plc (MAYBAK.ng) 2022 Annual Report – March 29, 2023 -
Corporate announcement, Dividends
May & Baker Nigeria Plc declares a final dividend of 0.3 NGN per share – March 27, 2023 -
Abridged Reports
May & Baker Nigeria Plc (MAYBAK.ng) 2022 Abridged Report – January 30, 2023 -
Interim Reports
May & Baker Nigeria Plc (MAYBAK.ng) Q32022 Interim Report – October 28, 2022
